Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2008

View Archived Issues

Eisai refocuses E-2007 program

Advanced Life Sciences plans cethromycin NDA submission

Recent patents cover new treatments for musculoskeletal and connective tissue disorders

Mesoblast expands phase II spinal fusion trial and accelerates plans for phase III

CVX-045 active alone and with chemotherapy in cancer models

EP-128265 induces apoptosis in vivo

Symbollon reports results of IoGen phase III trial in fibrocystic breast-related pain

Takeda to acquire Millennium

Encouraging preliminary results reported for Ad35 tuberculosis vaccine

Preclinical data supports use of AAV vectors to deliver siRNA

ThromboGenics completes enrollment in phase II trial of microplasmin for acute stroke

Napo reports successful results from Glenmark's phase II trial of crofelemer in diarrhea

Fatty acid amide hydrolase inhibitor ameliorates pain in preclinical study

Glenmark completes preclinical development for GBR-500, plans to submit an IND application

TL-1892 active in paclitaxel- and docetaxel-resistant tumor models

Manhattan completes enrollment in phase IIa clinical study of topical PTH (1-34) in psoriasis

Z(Abeta3) binds to amyloid-beta(1-40), inhibits amyloid formation

Haemacure reports positive results from preclinical study of fibrin sealant Hemaseel HMN

SMT-D002 suppresses sebum levels by 90% in repeat-dose trial

Rituxan fails to meet primary endpoint in primary-progressive MS study

AtheroGenics reports interim results from phase III AGI-1067 diabetes trial

Oramed initiates phase IIa clinical trial for oral insulin

Kosan initiates phase II epothilone KOS-1584 trial in non-small cell lung cancer

Recent Janssen patents describe new treatment options for cardiovascular disorders

Recent Roche patent imparts new anti-HIV agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...